MedTrace Logo

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

NCT00895674 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2840

Last updated 2010-09-30

No results posted yet for this study

Summary

Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.

Conditions

  • Carcinoma, Renal Cell
  • Carcinoma, Renal Cell (Advanced)

Interventions

DRUG

Nexavar (Sorafenib, BAY43-9006)

Patients with a diagnosis of advanced RCC

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Argentina
  • Austria
  • China
  • Colombia
  • Czechia
  • France
  • Germany
  • Greece
  • Indonesia
  • Mexico
  • Netherlands
  • Philippines
  • Poland
  • Russia
  • Slovakia
  • Slovenia
  • South Korea
  • Sweden

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00895674 on ClinicalTrials.gov